Table 3 Candidate areas with chromosomal alterations characterizing non-muscle invasive bladder cancers with subsequent progression.
From: Chromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer
Chromosome | Cytoband | Physical position (hg17/NCBI build 35.1) | chromosomal changes of progressing tumors | Candidate genes (selection) | p (single SNPs) | p (segment) |
|---|---|---|---|---|---|---|
1 | p31.1-p22.3 | 82–86 Mb | CN gain | BCL10 | 0.003 | n.s. |
2 | q33.3-q34 | 208–213 Mb | CN gain | CREB1, MAP2 | 0.001 | 0.05 |
3 | p21-p14.3 | 42–64 Mb | CN gain | CCR-cluster | 0.01 | n.s. |
4 | p13 | 40–45 Mb | CN loss/LOH | 0.02 | n.s. | |
6 | q15-q23.2 | 89–133 Mb | CN loss/LOH | TPD52L1 | 0.01 | n.s. |
8 | p12-p11.21 | 33 M–43 Mb | CN loss/LOH | SFRP1, TACC1, FGFR1 | 0.01 | n.s. |
10 | p15.1-p14 | 3.5 M–13 Mb | CN gain | GATA3, NET1, PKCQ, IL15RA | 0.005 | n.s. |
10 | p11 | 30–36 Mb | CN gain | 0.005 | n.s. | |
15 | q25.3 | 84–85 Mb | CN loss | 0.01 | n.s. |